MAPT and Alzheimer disease: CSF tau phosphorylated at threonine 181/Aβ1–42 ratios (pTau/Aβ ratio) were proposed as one of the best predictors to discriminate AD conversion groups from non-conversion group; with a sensitivity of 81–88% and a specificity of 90–95% [4], [6].